Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba

Motaher Hossain, Kamrul Islam, Meagan Kelly, Leslie M Mayo Smith, Richelle C Charles, Ana A Weil, Taufiqur Rahman Bhuiyan, Pavol Kováč, Peng Xu, Stephen B Calderwood, Jakub K Simon, Wilbur H Chen, Michael Lock, Caroline E Lyon, Beth D Kirkpatrick, Mitchell Cohen, Myron M Levine, Marc Gurwith, Daniel T Leung, Andrew S Azman, Jason B Harris, Firdausi Qadri, Edward T Ryan, Motaher Hossain, Kamrul Islam, Meagan Kelly, Leslie M Mayo Smith, Richelle C Charles, Ana A Weil, Taufiqur Rahman Bhuiyan, Pavol Kováč, Peng Xu, Stephen B Calderwood, Jakub K Simon, Wilbur H Chen, Michael Lock, Caroline E Lyon, Beth D Kirkpatrick, Mitchell Cohen, Myron M Levine, Marc Gurwith, Daniel T Leung, Andrew S Azman, Jason B Harris, Firdausi Qadri, Edward T Ryan

Abstract

Background: Antibodies targeting O-specific polysaccharide (OSP) of Vibrio cholerae may protect against cholera; however, little is known about this immune response in infected immunologically naïve humans.

Methodology: We measured serum anti-OSP antibodies in adult North American volunteers experimentally infected with V. cholerae O1 Inaba El Tor N16961. We also measured vibriocidal and anti-cholera toxin B subunit (CtxB) antibodies and compared responses to those in matched cholera patients in Dhaka, Bangladesh, an area endemic for cholera.

Principal findings: We found prominent anti-OSP antibody responses following initial cholera infection: these responses were largely IgM and IgA, and highest to infecting serotype with significant cross-serotype reactivity. The anti-OSP responses peaked 10 days after infection and remained elevated over baseline for ≥ 6 months, correlated with vibriocidal responses, and may have been blunted in blood group O individuals (IgA anti-OSP). We found significant differences in immune responses between naïve and endemic zone cohorts, presumably reflecting previous exposure in the latter.

Conclusions: Our results define immune responses to O-specific polysaccharide in immunologically naive humans with cholera, find that they are largely IgM and IgA, may be blunted in blood group O individuals, and differ in a number of significant ways from responses in previously humans. These differences may explain in part varying degrees of protective efficacy afforded by cholera vaccination between these two populations.

Trial registration number: ClinicalTrials.gov NCT01895855.

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: Jakub K. Simon, Michael Lock, and Marc Gurwith were employed by PaxVax, Inc. Wilbur H. Chen, Caroline E. Lyon, Beth D. Kirkpatrick, Mitchell Cohen, and Myron M. Levine received research funding from PaxVax, Inc. Jakub K. Simon is currently employed by Merck & Co. All other authors report no potential conflicts.

Figures

Fig 1. OSP responses over time in…
Fig 1. OSP responses over time in North American volunteers (orange) and Bangladeshi cholera patients (green).
Dots represent individual responses at each time since infection (jittered) for IgM (A-B), IgA (C-D) and IgG (E-F). Initial data points for Bangladeshi samples assigned day 3 from presumed date of infection. Lines represent LOESS curve fit to response data from each group and horizontal bars represent the geometric mean titer for each time point. Please refer to Supplemental S1–S3 Figs for detailed statistical comparisons among values.
Fig 2. Anti-cholera toxin B (CtxB) responses…
Fig 2. Anti-cholera toxin B (CtxB) responses in North American volunteers (orange) and Bangladeshi cholera patients (green).
Dots represent individual responses at each time since infection (jittered) for IgM (A), IgA (B) and IgG (C). Initial data points for Bangladeshi samples assigned day 3 from presumed date of infection. Lines represent LOESS curve fit to response data from each group and horizontal bars represent the geometric mean titer for each time point. Please refer to Supplemental S4 Fig for detailed statistical comparisons among values.
Fig 3. Vibriocidal responses over time in…
Fig 3. Vibriocidal responses over time in North American volunteers (orange) and Bangladeshi cholera patients (green).
Dots represent individual responses at each time since infection (jittered) for vibriocidal titers to Inaba (A) and Ogawa (B) serotypes. Initial data points for Bangladeshi samples assigned day 3 from presumed date of infection. Lines represent LOESS curve fit to response data from each group and horizontal bars represent the geometric mean titer for each time point. Please refer to Supplemental S5 Fig for detailed statistical comparisons among values.
Fig 4. Fold-changes of anti-Inaba OSP IgA…
Fig 4. Fold-changes of anti-Inaba OSP IgA responses by O versus non-O blood group status.
Distribution of fold-changes of anti-Inaba OSP IgA responses from pre-infection to day 10 following experimental infection of North American volunteers with V. cholerae O1 by O versus non-O blood group status. Colored ticks on x-axis illustrate the values of the fold-change for each participant.

References

    1. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012;379(9835):2466–76. Epub 2012/07/04. 10.1016/S0140-6736(12)60436-X .
    1. Stroeher UH, Karageorgos LE, Morona R, Manning PA. Serotype conversion in Vibrio cholerae O1. Proc Natl Acad Sci U S A. 1992;89(7):2566–70. Epub 1992/04/01. 10.1073/pnas.89.7.2566 .
    1. Hisatsune K, Kondo S, Isshiki Y, Iguchi T, Haishima Y. Occurrence of 2-O-methyl-N-(3-deoxy-L-glycero-tetronyl)-D-perosamine (4-amino-4,6-dideoxy-D-manno-pyranose) in lipopolysaccharide from Ogawa but not from Inaba O forms of O1 Vibrio cholerae. Biochem Biophys Res Commun. 1993;190(1):302–7. Epub 1993/01/15. 10.1006/bbrc.1993.1046 .
    1. Harris AM, Chowdhury F, Begum YA, Khan AI, Faruque AS, Svennerholm AM, et al. Shifting prevalence of major diarrheal pathogens in patients seeking hospital care during floods in 1998, 2004, and 2007 in Dhaka, Bangladesh. Am J Trop Med Hyg. 2008;79(5):708–14. Epub 2008/11/05. .
    1. Xu P, Alam MM, Kalsy A, Charles RC, Calderwood SB, Qadri F, et al. Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug Chem. 2011;22(10):2179–85. Epub 2011/09/09. 10.1021/bc2001984 .
    1. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J Infect Dis. 1994;169(3):709–10. Epub 1994/03/01. 10.1093/infdis/169.3.709 .
    1. Qadri F, Wenneras C, Albert MJ, Hossain J, Mannoor K, Begum YA, et al. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun. 1997;65(9):3571–6. Epub 1997/09/01. .
    1. Waldor MK, Colwell R, Mekalanos JJ. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc Natl Acad Sci U S A. 1994;91(24):11388–92. Epub 1994/11/22. 10.1073/pnas.91.24.11388 .
    1. Johnson RA, Uddin T, Aktar A, Mohasin M, Alam MM, Chowdhury F, et al. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin Vaccine Immunol. 2012;19(11):1712–21. Epub 2012/09/21. 10.1128/CVI.00321-12 .
    1. Uddin T, Aktar A, Xu P, Johnson RA, Rahman MA, Leung DT, et al. Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera. Am J Trop Med Hyg. 2014;90(5):873–81. Epub 2014/04/02. 10.4269/ajtmh.13-0498 .
    1. Leung DT, Uddin T, Xu P, Aktar A, Johnson RA, Rahman MA, et al. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol. 2013;20(6):780–8. Epub 2013/03/22. 10.1128/CVI.00035-13 .
    1. Aktar A, Rahman MA, Afrin S, Akter A, Uddin T, Yasmin T, et al. Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. PLoS Negl Trop Dis. 2018;12(4):e0006399 10.1371/journal.pntd.0006399 .
    1. Aktar A, Rahman MA, Afrin S, Faruk MO, Uddin T, Akter A, et al. O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol. 2016;23(5):427–35. Epub 2016/03/25. 10.1128/CVI.00647-15 .
    1. Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, et al. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Negl Trop Dis. 2018;12(4):e0006376 Epub 2018/04/07. 10.1371/journal.pntd.0006376 .
    1. Falkard B, Charles RC, Matias WR, Mayo-Smith LM, Jerome JG, Offord ES, et al. Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults. PLoS Negl Trop Dis. 2019;13(1):e0007057 10.1371/journal.pntd.0007057 .
    1. Matias WR, Falkard B, Charles RC, Mayo-Smith LM, Teng JE, Xu P, et al. Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults. PLoS Negl Trop Dis. 2016;10(6):e0004753 10.1371/journal.pntd.0004753 .
    1. Iyer AS, Bouhenia M, Rumunu J, Abubakar A, Gruninger RJ, Pita J, et al. Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan. Sci Rep. 2016;6:35742 10.1038/srep35742 .
    1. Saha D, LaRocque RC, Khan AI, Harris JB, Begum YA, Akramuzzaman SM, et al. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J Infect Dis. 2004;189(12):2318–22. Epub 2004/06/08. 10.1086/421275 .
    1. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis. 2008;2(4):e221 Epub 2008/04/10. 10.1371/journal.pntd.0000221 .
    1. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun. 1993;61(2):729–33. .
    1. Jayasekera CR, Harris JB, Bhuiyan S, Chowdhury F, Khan AI, Faruque AS, et al. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis. 2008;198(7):1055–61. Epub 2008/08/30. 10.1086/591500 .
    1. Kendall EA, Tarique AA, Hossain A, Alam MM, Arifuzzaman M, Akhtar N, et al. Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect Immun. 2009;78(1):253–9. Epub 2009/10/28. 10.1128/IAI.00868-09 .
    1. Alam MM, Riyadh MA, Fatema K, Rahman MA, Akhtar N, Ahmed T, et al. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol. 2011;18(5):844–50. Epub 2011/02/25. 10.1128/CVI.00562-10 .
    1. Chen WH, Cohen MB, Kirkpatrick BD, Brady RC, Galloway D, Gurwith M, et al. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016;62(11):1329–35. Epub 2016/03/24. 10.1093/cid/ciw145 .
    1. Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, et al. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae. Clin Vaccine Immunol. 2016;24 (1)(1):pii: e00470–16. Epub 2016/11/17. 10.1128/CVI.00470-16 .
    1. Haney DJ, Lock MD, Simon JK, Harris J, Gurwith M. Antibody-Based Correlates of Protection Against Cholera Analysis of a Challenge Study in a Cholera-Naive Population. Clin Vaccine Immunol. 2017;pii: CVI.00098–17. Epub 2017 May 31. 10.1128/CVI.00098-17 .
    1. Yang JS, An SJ, Jang MS, Song M, Han SH. IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity. PLoS One. 2019;14(3):e0213507 10.1371/journal.pone.0213507 .
    1. Villeneuve S, Souchon H, Riottot MM, Mazie JC, Lei P, Glaudemans CP, et al. Crystal structure of an anti-carbohydrate antibody directed against Vibrio cholerae O1 in complex with antigen: molecular basis for serotype specificity. Proc Natl Acad Sci U S A. 2000;97(15):8433–8. 10.1073/pnas.060022997 .
    1. Dallas WS, Falkow S. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin. Nature. 1980;288(5790):499–501. 10.1038/288499a0 .
    1. Sixma TK, Pronk SE, Kalk KH, Wartna ES, van Zanten BA, Witholt B, et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature. 1991;351(6325):371–7. 10.1038/351371a0 .
    1. Karlsson EK, Harris JB, Tabrizi S, Rahman A, Shlyakhter I, Patterson N, et al. Natural selection in a bangladeshi population from the cholera-endemic ganges river delta. Sci Transl Med. 2013;5(192):192ra86. 10.1126/scitranslmed.3006338 .
    1. Midani FS, Weil AA, Chowdhury F, Begum YA, Khan AI, Debela MD, et al. Human Gut Microbiota Predicts Susceptibility to Vibrio cholerae Infection. J Infect Dis. 2018;218(4):645–53. 10.1093/infdis/jiy192 .
    1. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, Abrego P, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1999;180(5):1709–12. 10.1086/315051 .
    1. Valcin CL, Severe K, Riche CT, Anglade BS, Moise CG, Woodworth M, et al. Predictors of disease severity in patients admitted to a cholera treatment center in urban Haiti. Am J Trop Med Hyg. 2013;89(4):625–32. 10.4269/ajtmh.13-0170 .
    1. Nelson EJ, Harris JB, Morris JG Jr., Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Microbiol. 2009;7(10):693–702. Epub 2009/09/17. 10.1038/nrmicro2204 .
    1. Weil AA, Khan AI, Chowdhury F, Larocque RC, Faruque AS, Ryan ET, et al. Clinical outcomes in household contacts of patients with cholera in Bangladesh. Clin Infect Dis. 2009;49(10):1473–9. 10.1086/644779 .
    1. Harris JB, Khan AI, LaRocque RC, Dorer DJ, Chowdhury F, Faruque AS, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun. 2005;73(11):7422–7. 10.1128/IAI.73.11.7422-7427.2005 .
    1. Lagos R, Avendano A, Prado V, Horwitz I, Wasserman S, Losonsky G, et al. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun. 1995;63(2):707–9. Epub 1995/02/01. .
    1. Arifuzzaman M, Ahmed T, Rahman MA, Chowdhury F, Rashu R, Khan AI, et al. Individuals with Le(a+b-) blood group have increased susceptibility to symptomatic vibrio cholerae O1 infection. PLoS Negl Trop Dis. 2011;5(12):e1413 10.1371/journal.pntd.0001413 .
    1. Cooling L. Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev. 2015;28(3):801–70. 10.1128/CMR.00109-14 .
    1. Kuhlmann FM, Santhanam S, Kumar P, Luo Q, Ciorba MA, Fleckenstein JM. Blood Group O-Dependent Cellular Responses to Cholera Toxin: Parallel Clinical and Epidemiological Links to Severe Cholera. Am J Trop Med Hyg. 2016;95(2):440–3. 10.4269/ajtmh.16-0161 .
    1. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Huda S, et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis. 1989;159(4):770–3. 10.1093/infdis/159.4.770 .
    1. Ramamurthy T, Wagener D, Chowdhury G, Majumder PP. A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response. Clin Vaccine Immunol. 2010;17(8):1232–7. 10.1128/CVI.00123-10 .
    1. Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol. 2001;167(5):2861–8. 10.4049/jimmunol.167.5.2861 .
    1. Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun. 1999;67(12):6341–5. .
    1. Gilmartin AA, Petri WA Jr. Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response. Philos Trans R Soc Lond B Biol Sci. 2015;370 (1671):pii: 20140143. 10.1098/rstb.2014.0143 .
    1. Sow SO, Tapia MD, Chen WH, Haidara FC, Kotloff KL, Pasetti MF, et al. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator. Clin Vaccine Immunol. 2017;24(12): pii: e00265–17. 10.1128/CVI.00265-17 .
    1. Gotuzzo E, Butron B, Seas C, Penny M, Ruiz R, Losonsky G, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993;61(9):3994–7. .
    1. Domman D, Chowdhury F, Khan AI, Dorman MJ, Mutreja A, Uddin MI, et al. Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. Nat Genet. 2018;50(7):951–5. 10.1038/s41588-018-0150-8 .

Source: PubMed

3
Se inscrever